Zura Bio Ltd financial data

Symbol
ZURA, ZURAW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4225 Executive Square, Suite 600, La Jolla, California
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
JATT Acquisition Corp (to 3/21/2023)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 724 % +86.3%
Debt-to-equity 21.8 % -75.3%
Return On Equity -40.2 % +92.5%
Return On Assets -28.7 % +71.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.6M shares +748%
Common Stock, Shares, Outstanding 63.7M shares +47.8%
Entity Public Float 357M USD +160%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 74.9M shares +118%
Weighted Average Number of Shares Outstanding, Diluted 74.9M shares +118%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20M USD -59.3%
General and Administrative Expense 21.1M USD +119%
Operating Income (Loss) -41.2M USD +4.21%
Nonoperating Income (Expense) 1.43M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -34.8M USD +44.2%
Net Income (Loss) Attributable to Parent -34.8M USD +54.3%
Earnings Per Share, Basic 1.79 USD/shares -100%
Earnings Per Share, Diluted 1.79 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 99.8M USD +723875%
Assets, Current 189M USD +67.2%
Property, Plant and Equipment, Net 25K USD
Assets 190M USD +67.2%
Accounts Payable, Current 990K USD -86%
Accrued Liabilities, Current 1.11M USD +457%
Liabilities, Current 15.1M USD -24.4%
Liabilities 17.4M USD -20.8%
Retained Earnings (Accumulated Deficit) -122M USD -40.1%
Stockholders' Equity Attributable to Parent 157M USD +127%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 158M USD +124%
Liabilities and Equity 190M USD +67.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.98M USD -53%
Net Cash Provided by (Used in) Financing Activities 45.7M USD +357%
Net Cash Provided by (Used in) Investing Activities -5.01M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 63.7M shares +47.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -215K USD -959%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 188M USD +67.1%
Deferred Tax Assets, Valuation Allowance 17.9M USD +179%
Deferred Tax Assets, Gross 17.9M USD +179%
Payments to Acquire Property, Plant, and Equipment 7K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.95M USD +431%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 278M USD +78.7%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 10.3M USD +26.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%